ATE265532T1 - Monoklonaler antikörper br110 und dessen anwendung - Google Patents
Monoklonaler antikörper br110 und dessen anwendungInfo
- Publication number
- ATE265532T1 ATE265532T1 AT96936244T AT96936244T ATE265532T1 AT E265532 T1 ATE265532 T1 AT E265532T1 AT 96936244 T AT96936244 T AT 96936244T AT 96936244 T AT96936244 T AT 96936244T AT E265532 T1 ATE265532 T1 AT E265532T1
- Authority
- AT
- Austria
- Prior art keywords
- antigen
- application
- monoclonal antibody
- complex
- ligands
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US564195P | 1995-10-19 | 1995-10-19 | |
| PCT/US1996/016070 WO1997014796A1 (en) | 1995-10-19 | 1996-10-07 | Monoclonal antibody br110 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE265532T1 true ATE265532T1 (de) | 2004-05-15 |
Family
ID=21716930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96936244T ATE265532T1 (de) | 1995-10-19 | 1996-10-07 | Monoklonaler antikörper br110 und dessen anwendung |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5840854A (de) |
| EP (1) | EP0856054B1 (de) |
| JP (1) | JP2001501801A (de) |
| AT (1) | ATE265532T1 (de) |
| AU (1) | AU7394296A (de) |
| CA (1) | CA2235269C (de) |
| DE (1) | DE69632333T2 (de) |
| ES (1) | ES2219699T3 (de) |
| IL (1) | IL123294A0 (de) |
| NO (1) | NO321548B1 (de) |
| WO (1) | WO1997014796A1 (de) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7354587B1 (en) * | 1994-07-06 | 2008-04-08 | Immunomedics, Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| US6366762B1 (en) * | 1999-03-31 | 2002-04-02 | Qualcomm, Inc. | System and method for measuring round trip delay on the paging and access channels |
| US6617432B1 (en) * | 1999-10-15 | 2003-09-09 | University Of Pittsburgh | Nuclear matrix proteins polynucleotide sequences encoding them and their use |
| US20030009781A1 (en) * | 2001-03-29 | 2003-01-09 | Allen Keith D. | Transgenic mice containing Kir3.3 potassium channel gene disruptions |
| US20020155109A1 (en) * | 2001-04-20 | 2002-10-24 | Lynch David H. | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 |
| US8435529B2 (en) | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
| CA2478047C (en) | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
| US9770517B2 (en) * | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| US9701754B1 (en) | 2002-10-23 | 2017-07-11 | City Of Hope | Covalent disulfide-linked diabodies and uses thereof |
| US20080131428A1 (en) * | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US7420041B2 (en) * | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US20080213267A1 (en) * | 2006-02-24 | 2008-09-04 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US20080305104A1 (en) * | 2006-02-24 | 2008-12-11 | Young David S F | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| EP1996716B1 (de) | 2006-03-20 | 2011-05-11 | The Regents of the University of California | Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting |
| JP4689521B2 (ja) * | 2006-04-07 | 2011-05-25 | 財団法人電力中央研究所 | 抗鉛モノクローナル抗体 |
| US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
| EP3495000A1 (de) | 2009-02-17 | 2019-06-12 | Cornell Research Foundation, Inc. | Verfahren und kits zur diagnose von krebs und vorhersage des therapeutischen werts |
| MX337600B (es) | 2009-12-02 | 2016-03-11 | Imaginab Inc | Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antigeno de membrana especifico para prostata de humano (psma) y metodos para su uso. |
| SG10201503904XA (en) * | 2010-05-17 | 2015-06-29 | Livtech Inc | Anti-human trop-2 antibody having antitumor activity in vivo |
| JPWO2011155579A1 (ja) * | 2010-06-10 | 2013-08-15 | 北海道公立大学法人 札幌医科大学 | 抗Ｔｒｏｐ−２抗体 |
| US8871908B2 (en) | 2011-11-11 | 2014-10-28 | Rinat Neuroscience Corp. | Antibodies specific for Trop-2 and their uses |
| US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| JP6447933B2 (ja) | 2014-02-21 | 2019-01-09 | アイビーシー ファーマスーティカルズ，インコーポレイテッド | Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療 |
| US9797907B2 (en) | 2015-04-22 | 2017-10-24 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells |
| KR20250008141A (ko) | 2015-08-07 | 2025-01-14 | 이미지냅 인코포레이티드 | 분자를 표적화하기 위한 항원 결합 구조체 |
| WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
| WO2020094670A1 (en) | 2018-11-05 | 2020-05-14 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
| CN115398010A (zh) | 2020-03-20 | 2022-11-25 | 免疫医疗公司 | 用于戈沙妥珠单抗疗法的生物标志物 |
| KR20230086712A (ko) | 2020-10-14 | 2023-06-15 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 항-trop-2 항체, 이의 항원-결합 단편 또는 이의 돌연변이체, 및 이의 의학적 용도 |
| CN115429893A (zh) | 2021-06-02 | 2022-12-06 | 百奥泰生物制药股份有限公司 | 药物偶联物及其用途 |
| JP2024536798A (ja) | 2021-09-23 | 2024-10-08 | シャンハイ ハンソー バイオメディカル カンパニー リミテッド | 抗体薬物コンジュゲート並びにその製造方法及び医薬用途 |
| CN119212731A (zh) | 2022-03-23 | 2024-12-27 | 新锐生物技术公司 | 用于靶向表达Trop-2的肿瘤的抗体缀合物 |
| EP4545099A1 (de) | 2022-06-27 | 2025-04-30 | Bio-Thera Solutions, Ltd. | Verfahren zur behandlung von soliden tumoren |
| AR132494A1 (es) | 2023-04-24 | 2025-07-02 | Merck Sharp & Dohme Llc | Aglutinantes de trop2 y conjugados de estos |
| WO2025019790A1 (en) | 2023-07-19 | 2025-01-23 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc |
| WO2026092759A1 (en) | 2024-11-04 | 2026-05-07 | Modex Therapeutics, Inc. | Multispecific antibodies and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5185254A (en) * | 1988-12-29 | 1993-02-09 | The Wistar Institute | Gene family of tumor-associated antigens |
| AU641392B2 (en) * | 1989-04-21 | 1993-09-23 | Protein Design Laboratories, Inc. | Recombinant antibody-toxin fusion protein |
| EP0609292A4 (en) * | 1991-10-18 | 1995-10-25 | Wistar Inst | Soluble variants of type i membrane proteins, and methods of using them. |
-
1996
- 1996-10-07 AT AT96936244T patent/ATE265532T1/de not_active IP Right Cessation
- 1996-10-07 WO PCT/US1996/016070 patent/WO1997014796A1/en not_active Ceased
- 1996-10-07 EP EP96936244A patent/EP0856054B1/de not_active Expired - Lifetime
- 1996-10-07 DE DE69632333T patent/DE69632333T2/de not_active Expired - Fee Related
- 1996-10-07 IL IL12329496A patent/IL123294A0/xx unknown
- 1996-10-07 CA CA002235269A patent/CA2235269C/en not_active Expired - Fee Related
- 1996-10-07 ES ES96936244T patent/ES2219699T3/es not_active Expired - Lifetime
- 1996-10-07 JP JP09515854A patent/JP2001501801A/ja not_active Ceased
- 1996-10-07 US US08/726,528 patent/US5840854A/en not_active Expired - Fee Related
- 1996-10-07 AU AU73942/96A patent/AU7394296A/en not_active Abandoned
-
1998
- 1998-04-17 NO NO19981745A patent/NO321548B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US5840854A (en) | 1998-11-24 |
| WO1997014796A1 (en) | 1997-04-24 |
| EP0856054A1 (de) | 1998-08-05 |
| CA2235269C (en) | 2006-09-19 |
| MX9802129A (es) | 1998-05-31 |
| NO981745D0 (no) | 1998-04-17 |
| DE69632333T2 (de) | 2004-12-30 |
| IL123294A0 (en) | 1998-09-24 |
| AU7394296A (en) | 1997-05-07 |
| JP2001501801A (ja) | 2001-02-13 |
| CA2235269A1 (en) | 1997-04-24 |
| ES2219699T3 (es) | 2004-12-01 |
| NO981745L (no) | 1998-04-17 |
| EP0856054B1 (de) | 2004-04-28 |
| NO321548B1 (no) | 2006-05-29 |
| DE69632333D1 (de) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69632333D1 (de) | Monoklonaler antikörper br110 und dessen anwendung | |
| PT724456E (pt) | Anticorpos contra cd4 | |
| WO1997046589A3 (en) | Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods | |
| ES2106195T3 (es) | Anticuerpo igg aglicosilado anti cd3. | |
| PT973550E (pt) | Anticorpos antagonistas anti-integrina avb3 | |
| DK1360500T3 (da) | Fremgangsmåde til selektiv målretning | |
| GB2383331A (en) | Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof | |
| ATE477275T1 (de) | Antikörper gegen cd28 | |
| ATE412432T1 (de) | Internalisierende erbb2 antikörper | |
| GEP20105118B (en) | Anti-vegf antibodies | |
| MX9602971A (es) | Anticuerpos humanizados contra la molecula vla-4 de adhesion de leucocitos. | |
| FI963004A7 (fi) | Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita | |
| ATE509955T1 (de) | Humanisierte kollagen-antikörper und damit verbundene verfahren | |
| DE69433114D1 (de) | Metallion-ligand koordinationskomplexe, antikorper dagegen und tests die solche antikorper verwenden | |
| CA2348026A1 (en) | Antibodies against semp1, methods for their production and uses thereof | |
| ATE217086T1 (de) | Herstellung von photoprotein konjugaten und verfahren zu ihrer verwendung | |
| NZ305083A (en) | Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response | |
| DE59608073D1 (de) | Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid | |
| NO20001051D0 (no) | Monoklonale antistoffer som binder testosteron | |
| DK1121594T3 (da) | Fremgangsmåder til identifikation af hot-spot remanenser af bindende proteiner og små forbindelser som binder til samme | |
| SE9902155L (sv) | Serum antibodies | |
| AU6068000A (en) | Peptide ligands that bind igm antibodies and block interaction with antigen | |
| BR1100555B1 (pt) | anticorpos monoclonais humanizados. | |
| HUP0003029A2 (hu) | Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |